ISRCTN14409785进行中（未招募）未知
Double-blinded placebo-controlled crossover study of Mesenchymal Intravenous Stromal cell Infusions in children with recessive dystrophic Epidermolysis Bullosa
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of RDEB characterised by partial or complete C7 deficiency including generalised severe and generalised intermediate subtypes
- •2. Aged >6 months and <16 years at time of enrolment
- •3. Responsible parent/guardian has voluntarily signed and dated an Informed Consent Form (ICF) prior to the first study intervention. Whenever the minor child is able to give consent, the minor’s assent will be obtained in addition to the signed consent of the minor’s legal guardian.
排除标准
- •Current participant exclusion criteria as of 07/03/2023:
- •1. Other subtypes of EB such as EB simplex, EB junctional, dominant dystrophic EB, and Kindler EB
- •2. Received oral or topical corticosteroids for >7 consecutive days within 30 days or enrolment into this study, except for treatment with oral budesonide
- •3. Known allergy to any of the constituents of the investigational product
- •4. Signs of active infection that require treatment with oral or intravenous antibiotics within 7 days of screening
- •5. History or evidence of active malignancy, including cutaneous squamous cell carcinoma
- •6. Positive C7 ELISA and positive indirect immunofluorescence (IIF) with binding to the base of salt split skin at screening
- •7. Pregnant or of child-bearing potential who are not abstinent or practicing an acceptable means of contraception, as determined by the Investigator, for the duration of the treatment phase
- •8. Received MSC infusions in the last 9 months
- •9. Simultaneous or previous participation in any interventional trial within 3 months before entering this trial. Participation in simultaneous registry and diagnostic trials during the trial is allowed.
- •____________
- •Previous participant exclusion criteria as of 22/04/2022 to 07/03/2023:
- •1. Other subtypes of EB such as EB simplex, EB junctional, dominant dystrophic EB, and Kindler EB
- •2. Received oral or topical corticosteroids for >7 consecutive days within 30 days or enrolment into this study, except for treatment with oral budesonide
- •3. Known allergy to any of the constituents of the investigational product
- •4. Signs of active infection that require treatment with oral or intravenous antibiotics within 7 days of screening
- •5. History or evidence of active malignancy, including cutaneous squamous cell carcinoma
- •6. Positive C7 ELISA and positive indirect immunofluorescence (IIF) with binding to the base of salt split skin
- •7. Pregnant or of child-bearing potential who are not abstinent or practicing an acceptable means of contraception, as determined by the Investigator, for the duration of the treatment phase
- •8. Received MSC infusions in the last 9 months
- •9. Simultaneous or previous participation in any interventional trial within 3 months before entering this trial. Participation in simultaneous registry and diagnostic trials during the trial is allowed.
- •____________
- •Previous participant exclusion criteria:
- •1. Other subtypes of EB such as EB simplex, EB junctional, dominant dystrophic EB, and Kindler EB
- •2. Received oral or topical corticosteroids for >1 week within 30 days of enrolment into this study
- •3. Known allergy to any of the constituents of the investigational product
- •4. Signs of active infection that require treatment with oral or intravenous antibiotics within 7 days of screening
- •5. History or evidence of active malignancy, including cutaneous squamous cell carcinoma
- •6. Positive C7 ELISA and positive indirect immunofluorescence (IIF) with binding to the base of salt split skin
- •7. Pregnant or of child-bearing potential who are not abstinent or practicing an acceptable means of contraception, as determined by the Investigator, for the duration of the treatment phase
- •8. Received MSC infusions in the last 9 months
- •9. Simultaneous or previous participation in any interventional trial within 3 months before entering this trial. Participation in simultaneous registry and diagnostic trials during the trial is allowed.
研究者
相似试验
已完成
2 期
The use of APL510 to improve the length of day time sleep in subjects working permanent night-shiftsMental and Behavioural DisordersNonorganic sleep disordersInsomniaISRCTN15733268Alliance Pharmaceuticals Ltd (UK)44
已完成
2 期
1.5 versus 3.0 mg APL510 to normalise sleep patterns in elderly subjects with insomniaMental and Behavioural DisordersNonorganic sleep disordersInsomniaISRCTN82088636Alliance Pharmaceuticals Ltd (UK)80
进行中（未招募）
不适用
Double-blind, placebo controlled cross-over study to assess efficacy of Levetiracetam in paediatric and childhood Tourette syndrome. Estudio cruzado, aleatorizado, doble ciego controlado con placebo, para evaluar la eficacia del Levetiracetam en el control de los tics de pacientes pediátricos y adolescentes con síndrome de Gilles de la TouretteTourette syndromeEUCTR2005-002041-40-ESHospital Sant Joan de Déu
进行中（未招募）
不适用
Double-blind, placebo controlled cross-over study to assess the efficacy of Levetiracetam in paediatric and childhood non-epileptic myoclonusEstudio cruzado, aleatorizado, doble ciego controlado con placebo, para evaluar la eficacia del Levetiracetam en el tratamiento del mioclonus no epiléctico en pacientes pediátricos y adolescentesEUCTR2005-002042-19-ESHospital Sant Joan de Déu
进行中（未招募）
1 期
A double-blind placebo controlled cross-over study to determine if 1.5 and 3mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating sleep onset. - N/AEUCTR2004-003939-32-GBAlliance Pharmaceuticals Ltd80